Attendees

ISPOR 43rd Health Technology Assessment Roundtable [Europe]
Sunday, 11 November 2018 – 08:30 – 17:30
Centre de Convencions Internacional de Barcelona (Room: 212)
Barcelona, Spain

Chair
Wim Goettsch, PhD, MSc
Special Advisor, HTA
Zorginstituut Nederland (ZIN)
Diemen, Netherlands

HTA Council Chair
Professor Finn Børlum Kristensen, MD, PhD
Professor, Faculty of Health Sciences
University of Southern Denmark
Odense, Denmark

European Commission
Flora Giorgio
Policy Officer, DG Sanco
European Commission
Brussels, Belgium

World Health Organization
Sarah Garner, PhD, BPharm
Coordinator, Innovation, Access and Use, Essential Medicines and Health Products
World Health Organization
Geneva, Switzerland

EUnetHTA
Luciana Ballini, MSc
Chair, EUnetHTA JA3 Plenary Assembly
Senior Researcher, Regional Agency for Health (ASSR)
Emilia Romagna, Italy
Invited Speakers

Patricia Danzon, PhD
Celia Moh Professor Emeritus, The Wharton School
University of Pennsylvania
Philadelphia, PA, USA

Jan Geissler
Chair, ISPOR Patient Representatives Roundtable - Europe
Co-founder, CML Advocates Network
Board Member, Acute Leukemia Advocates Network
Co-Chair FUTURES Team, EUPATI
CEO, Patvocates
Munich, Germany

Pall Jonsson, PhD, MSc
Associate Director
National Institute for Health and Clinical Excellence (NICE)
Manchester, England, United Kingdom

Amr Makady, PhD, PharmD
Pharmacoeconomic Assessor & Policy Advisor
Zorginstituut Nederland (ZIN)
Diemen, Netherlands

Harriet Unsworth, PhD
Senior Technical Analyst, Medical Technologies
National Institute for Health and Clinical Excellence (NICE)
Manchester, England, United Kingdom

Shirley Wang, PhD, ScM
Epidemiologist, Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham & Women’s Hospital
Boston, MA, USA
Attendees

**Austria**
**Gottfried Endel, MD**
Head of Department for Evidence Based Economic Health Care
Main Association of Austrian Social Security Institutions
Vienna, Austria

**Ingrid Rosian-Schikuta, Mag**
Deputy Head, Health Economics Department
Gesundheit Österreich GmbH (GÖG)
Vienna, Austria

**Belgium**
**Francis Arickx**
Head, Directorate Pharmaceutical Policy
National Institute for Health and Disability Insurance (RIZIV INAMI)
Brussels, Belgium

**Frank Hulstaert, MD, MSc**
Senior Researcher
Federal Centre for Health Care Knowledge (KCE)
Brussels, Belgium

**Bosnia and Herzegovina**
**Siniša Stević, MD, MS**
Director
Agency for Certification, Accreditation and Health Care Improvement (ASKVA)
Banja Luka, Bosnia and Herzegovina

**Croatia**
**Mirjana Huić, MD, PhD**
Clinical Pharmacologist and Toxicologist
Assistant Director, Department for Development, Research and Health Technology Assessment
Agency for Quality and Accreditation in Health Care and Social Welfare
Zagreb, Croatia
Attendees

Jelena Matuzović, dr med
Head, Department for Medicines
Croatian Institute for Health Insurance
Zagreb, Croatia

Denmark
Camilla Nielsen, PhD, MSc
Research Director, Health Technology Assessment & Health Services Research
DEFACTUM
Aarhus, Denmark

Finland
Piia Rannanheimo, MSc
Pharmacoeconomist
Finnish Medicines Agency (FIMEA)
Kuopio, Finland

Miia Turpeinen, MD, PhD, MBA
Head
National HTA Coordination Unit (FinCCHTA)
Oulu, Finland

France
Chantal Guilhaume, PharmD
Scientific Project Manager, EUnetHTA JA3
Haute Autorité de Santé (HAS)
Saint-Denis La Plaine, France

Germany
Dr. Veronika Deák
Scientific Advisor
Gemeinsamer Bundesausschuss (G-BA, Federal Joint Committee)
Berlin, Germany

Alric Rüther, dr med, PhD
Head, International Affairs
Institute for Quality and Efficiency in Health Care (IQWiG)
Cologne, Germany
Attendees

Greece
Spyridon Goulas, MD
Supervisor
National Organization for Health Care Provision (EOPYY)
Athens, Greece

Hungary
Fanni Ispán, MSc
Reimbursement Analyst
National Health Insurance Fund of Hungary
Budapest, Hungary

Gergő Merész, MSc
Head, Department of Health Technology Assessment
National Institute of Pharmacy and Nutrition (NIPN)
Budapest, Hungary

Ireland
Lesley Tilson, PhD, BSc Pharm (Hons)
Deputy Director, National Centre for Pharmacoeconomics
St. James’s Hospital
Dublin, Ireland

Italy
Agnese Cangini, MSc
Health Economist
Agenzia Italiana del Farmaco (AIFA)
Rome, Italy

Kazakhstan
Kamilla Gaitova, PhD, MSc
Head, HTA Department
Republican Center for Health Development, Ministry of Health
Astana, Kazakhstan
Attendees

Latvia
Kristīna Brūvere
Senior Expert, Department of Pharmacy
Ministry of Health of Latvia
Riga, Latvia

Malta
Antonia Formosa
Director, Pharmaceutical Affairs
Ministry of Health
Valletta, Malta

Sylvana Magrin Sammut, MSc
Senior Pharmacist, Department Pharmaceutical Affairs
Ministry of Health
Valletta, Malta

Netherlands
Saskia Knies, PhD, MPhil
Senior Pharmacoeconomic Assessor
National Health Care Institute (ZIN)
Diemen, The Netherlands

Norway
Krystyna Hviding, PhD
Senior Advisor – HTA, HTA Unit
Norwegian Medicines Agency
Oslo, Norway

Øyvind Melien, MD, PhD, MSc
Department Director, Reviews and HTA
Norwegian Institute of Public Health
Oslo, Norway
Attendees

Poland
Iga Lipska, MD, PhD
Member, Economic Commission, Ministry of Health Poland
Chief Expert, National Health Fund
Warsaw, Poland

Roman Topór-Mądry, MD, PhD
President
Agency for Health Technology Assessment and Tariff System (AOTMiT)
Warsaw, Poland

Portugal
Rui Santos Ivo, PharmD
Vice President
INFARMED
Lisbon, Portugal

Romania
Silvia Gabriela Scintee, MD, PhD, MSc
Deputy General Director
National School of Public Health
Bucharest, Romania

Russian Federation
George Khachatryan, MD
Deputy Director, Department of Comprehensive Health Technology Assessment, FSBI "Center of Healthcare Quality Assessment and Control"
Ministry of Health of the Russian Federation
Moscow, Russia

Vitaly Omelyanovskiy, MD, PhD, DSc
General Director, Department of Comprehensive Health Technology Assessment, FSBI Center of Expertise and Quality Control of Medicines, Ministry of Health of the Russian Federation
Head, Financial Scientific Research Institute, Ministry of Finance of the Russian Federation
Head, Center for Health Technology Assessment, Russian Presidential Academy of National Economy and Public Administration
Moscow, Russia
Attendees

Serbia
Dragana Atanasijevic, MD, MSc
Health Technology Assessment Expert
National Institute for Public Health
Belgrade, Serbia

Slovakia
Tomas Tesar, PharmD, PhD, MBA
Member, Reimbursement Committee
Union Health Insurance Fund
Bratislava, Slovakia

Slovenia
Jure Mikolič, MA Pharm
Pharmacy Manager, Department of Medicine
Health Insurance Institute Slovenia
Ljubljana, Slovenia

Andrej Janžič, PhD, mag farm
Division for Pharmacoeconomics, Market Monitoring, and HTA
Agency for Medicinal Products and Medical Devices of the Republic of Slovenia
Ljubljana, Slovenia

Spain
Iñaki Imaz-Iglesia, MD, PhD
Senior Researcher
Instituto de Salud Carlos III (AETS-ISCIII)
Madrid, Spain

Leonor Varela Lema, PharmD, MSc
International Project Manager, Scientific Advice Unit
Galician Agency for Health Technology Assessment (AVALIA-T)
Santiago de Compostela, Spain
Attendees

Mireia Espallargues Carreras, MD, PhD
Responsible, Health Technology and Quality Assessment
Agency for Health Quality and Assessment of Catalonia (AQuAS)
Barcelona, Spain

Sweden
Sophie Werkö, PhD, MSc
Project Director, Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)
Chair, The International Network of Agencies for Health Technology Assessment (INAHTA)
Stockholm, Sweden

Turkey
Rabia Kahveci, MD, MScHTA
Professor, Ankara Numune Hospital
Chair, ANHTA (Ankara Numune HTA Unit)
Consultant, HTA Unit, Ministry of Health (Agency for Pharmaceuticals and Medical Devices)
Director, HTAi
Ankara, Turkey

Ukraine
Oresta Piniazhko, PhD, PharmD
Senior Lecturer, Department of Management and Economy of Pharmacy, Medicine Technology and Pharmacoeconomics, Postgraduate Faculty, Danylo Halytsky Lviv National Medical University
Member of Expert Committee, Ministry of Health of Ukraine
Lviv, Ukraine

United Kingdom
Meindert Boysen, PharmD, MSc
Director, Centre for Health Technology Evaluation
National Institute for Health and Clinical Excellence (NICE)
Manchester, England, United Kingdom

Anne Lee
Chief Pharmacist
Scottish Medicines Consortium (SMC)
Glasgow, Scotland, United Kingdom
Attendees

Observer
David Rogers, MBA
Policy Analyst
Bermuda Health Council
Hamilton, Bermuda

ISPOR Staff
Nancy Berg, CEO & Executive Director
Nadia Naaman, Senior Director, Scientific and Health Policy Initiatives
Julia Chamova, MBA, Director, Global Networks – Europe, Middle East, and Africa
Kelly Lenahan, MPH(c), Manager, Scientific and Health Policy Initiatives